Table 1.
Baseline characteristics before propensity matching scores, showing statistical comparisons between the CDS and no-CDS groups.
| CDS | No-CDS | Overall | χ 2 | p | |
|---|---|---|---|---|---|
| (N = 514) | (N = 5770) | (N = 6284) | |||
| Age | 3.521 | 0.172 | |||
| ≤49 | 61 (11.9%) | 644 (11.2%) | 705 (11.2%) | ||
| 50-64 | 186 (36.2%) | 1,884 (32.7%) | 2,070 (32.9%) | ||
| ≥65 | 267 (51.9%) | 3,242 (56.2%) | 3,509 (55.8%) | ||
| Sex | 0.972 | 0.324 | |||
| Female | 165 (32.1%) | 1,726 (29.9%) | 1,891 (30.1%) | ||
| Male | 349 (67.9%) | 4,044 (70.1%) | 4,393 (69.9%) | ||
| Race | 26.668 | <0.001 | |||
| White | 341 (66.3%) | 4,326 (75.0%) | 4,667 (74.3%) | ||
| Black | 71 (13.8%) | 739 (12.8%) | 810 (12.9%) | ||
| Other | 100 (19.5%) | 687 (11.9%) | 787 (12.5%) | ||
| Unknown | 2 (0.4%) | 18 (0.3%) | 20 (0.3%) | ||
| Marital status | 6.569 | 0.161 | |||
| Divorced | 41 (8.0%) | 503 (8.7%) | 544 (8.7%) | ||
| Married | 313 (60.9%) | 3,322 (57.6%) | 3,635 (57.8%) | ||
| Single | 61 (11.9%) | 893 (15.5%) | 954 (15.2%) | ||
| Widowed | 59 (11.5%) | 680 (11.8%) | 739 (11.8%) | ||
| Unknown | 40 (7.8%) | 372 (6.4%) | 412 (6.6%) | ||
| Primary Site | 148.950 | <0.001 | |||
| Body of stomach | 40 (7.8%) | 488 (8.5%) | 528 (8.4%) | ||
| Overlapping lesion of stomach | 48 (9.3%) | 378 (6.6%) | 426 (6.8%) | ||
| Stomach | 75 (14.6%) | 953 (16.5%) | 1,028 (16.4%) | ||
| Cardia and fundus of stomach | 140 (27.2%) | 2,756 (47.8%) | 2,896 (46.1%) | ||
| Gastric antrum and pylorus | 149 (29.0%) | 730 (12.7%) | 879 (14.0%) | ||
| Greater and lesser curvature | 62 (12.1%) | 465 (8.1%) | 527 (8.4%) | ||
| Grade | 69.774 | <0.001 | |||
| Grade I | 4 (0.8%) | 125 (2.2%) | 129 (2.1%) | ||
| Grade II | 128 (24.9%) | 1,342 (23.3%) | 1,470 (23.4%) | ||
| Grade III | 318 (61.9%) | 3,046 (52.8%) | 3,364 (53.5%) | ||
| Grade IV | 17 (3.3%) | 52 (0.9%) | 69 (1.1%) | ||
| Unknown | 47 (9.1%) | 1,205 (20.9%) | 1,252 (19.9%) | ||
| T | 543.500 | <0.001 | |||
| T0 | 0 (0%) | 33 (0.6%) | 33 (0.5%) | ||
| T1 | 48 (9.3%) | 1,185 (20.5%) | 1,233 (19.6%) | ||
| T2 | 28 (5.4%) | 174 (3.0%) | 202 (3.2%) | ||
| T3 | 173 (33.7%) | 730 (12.7%) | 903 (14.4%) | ||
| T4 | 216 (42.0%) | 866 (15.0%) | 1,082 (17.2%) | ||
| Tx | 49 (9.5%) | 2,782 (48.2%) | 2,831 (45.1%) | ||
| N | 849.840 | <0.001 | |||
| N0 | 101 (19.6%) | 2,036 (35.3%) | 2,137 (34.0%) | ||
| N1 | 140 (27.2%) | 2,189 (37.9%) | 2,329 (37.1%) | ||
| N2 | 110 (21.4%) | 258 (4.5%) | 368 (5.9%) | ||
| N3 | 134 (26.1%) | 170 (2.9%) | 304 (4.8%) | ||
| Nx | 29 (5.6%) | 1,117 (19.4%) | 1,146 (18.2%) | ||
| Chemotherapy | 0.429 | 0.512 | |||
| No | 221 (43.0%) | 2,389 (41.4%) | 2,610 (41.5%) | ||
| Yes | 293 (57.0%) | 3,381 (58.6%) | 3,674 (58.5%) | ||
| Survival months | |||||
| Mean (SD) | 16.0 (19.4) | 8.64 (12.6) | - | 329.13 | <0.001 |
| Median [Min, Max] | 9.00 [0, 103] | 4.00 [0, 107] | - | ||